Engineering bacterium for oral delivery of biological agent and application of engineering bacterium in preparation of medicine for treating psoriasis

By constructing engineered probiotics that can intelligently sense intestinal arabinose concentration, combined with IL-17A target antibody, long-term in-situ delivery of the gastrointestinal tract is achieved, solving the localization of existing biological agents in the treatment of moderate to severe psoriasis The problems of side effects and poor compliance improve the effectiveness and safety of treatment.

CN119020383APending Publication Date: 2024-11-26XIDIAN UNIV
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202411098100.2
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-08-12
Publication Date
2024-11-26

AI Technical Summary

Technical Problem

The existing biological preparations are used in the treatment of moderate to severe psoriasis and have local pain, erythema, rash and infection risks. The oral biological preparations are costly, have a long treatment cycle, poor patient compliance, and lack effective oral delivery strategies.

Method used

A engineered bacteria that delivers biological agents orally is designed, using the genetic circuits and functional elements that fit the chassis bacteria, to construct an engineered probiotic that can intelligently sense the concentration of intestinal arabinose through synthetic biological technology, and combines with IL-17A target antibodies. Achieve long-term in-situ delivery of the gastrointestinal tract and improve the treatment effect.

Benefits of technology

Long-term in-situ delivery of the gastrointestinal tract is achieved, local side effects are reduced, the effectiveness and safety of treatment are improved, patient compliance is enhanced, and new strategies for treating psoriasis and related complications are provided.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119020383A_ABST
    Figure CN119020383A_ABST
Patent Text Reader

Abstract

The invention discloses an engineering bacterium for oral delivery of a biological agent and application of the engineering bacterium in preparation of a medicine for treating psoriasis, and belongs to the technical field of biological medicines. The invention provides a recombinant plasmid. The recombinant plasmid comprises a plasmid vector, an arabinose response type promoter, a signal peptide and a coding gene of a single-chain antibody which are connected in sequence, the single-chain antibody is a psoriasis treatment load. The invention also provides an oral engineering bacterium, which comprises a chassis bacterium and a recombinant plasmid introduced into the chassis bacterium. The invention also provides an application of the recombinant plasmid or the oral engineering bacterium in preparation of a biological agent for treating psoriasis and / or related complications. The invention not only provides a new treatment strategy for psoriasis and related complications, but also provides a new basis for oral engineering probiotics for disease treatment.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention belongs to the field of biomedicine technology, and specifically relates to an engineered bacterium for oral delivery of biological preparations and its application in the preparation of a drug for treating psoriasis. Background Art

[0002] Psoriasis is an immune-mediated chronic, recurrent, inflammatory, systemic disease induced by the combined effects of genetics and the environment. It may cause serious complications such as psoriatic arthritis (PsA), infection, and cardiovascular disease. Since the core mechanism of psoriasis and its complications is the imbalance in the interaction between the innate and adaptive immune components of skin cells, immunosuppressive drugs are currently the first choice for the treatment of psoriasis. Treatment regimens based on topical medications or phototherapy are suitable for patients with milder symptoms. For moderate to severe patients, ordinary drugs can no longer achieve the expected therapeutic effect due to the severity of the disease and rapid progression. In recent years, biological agents have gradually attracted the attention and recognition of clinicians due to their accurate targets, high efficacy, and ease of use. They have also become a new method for patients with psoriasis and related complications to effectively control the disease.

[0003] Biologics approved for the treatment of psoriasis and related complications at home and abroad include tumor necrosis factor α (TNF-α) inhibitors, interleukin 12 / 23 (IL-12 / 23) inhibitors, and interleukin 17A (IL-17A) inhibitors. Most biologics are injected subcutaneously, and some special biologics, such as infliximab, are injected intravenously. In order to avoid systemic problems caused by systemic large-dose administration, subcutaneous injection has become the mainstream method of administration of biologics at this stage, with the advantages of small administration volume, slow absorption, low side effects, and convenient operation.

[0004] However, when administered by subcutaneous injection, local pain, erythema and rash will occur at the injection site, and local infection may occur, so the current biological preparations are still insufficient in terms of long-term safety and patient compliance. In addition, compared with oral small molecule drugs, biological preparations are expensive, have a longer treatment cycle, and require a high frequency of needles, resulting in poor patient compliance.

[0005] Therefore, finding new biological agent delivery strategies to improve the effectiveness, safety and patient compliance of psoriasis treatment is one of the core issues that need to be urgently addressed in the current research field of moderate to severe psoriasis treatment. Summary of the invention

[0006] In view of the defects existing in the above-mentioned prior art, the purpose of the present invention is to design and provide an engineered bacterium for oral delivery of biological agents and its application in the preparation of drugs for the treatment of psoriasis. The present invention starts with the design of gene circuits and functional elements that match the chassis bacteria, and selects probiotics suitable for oral administration as chassis bacteria, so that the engineered bacteria have the ability to colonize in the intestine for a long time. Further, by using synthetic biology technology, by editing the synthetic gene circuit, gene editing is performed with the arabinose promoter as the response element and PelB as the exocrine signal peptide, and an engineered probiotic that can intelligently sense the intestinal arabinose concentration and then exocrine therapeutic load is constructed. Finally, IL-17A is selected as the target, and the anti-IL-17A single-chain antibody screened is constructed on the recombinant plasmid through gene synthesis technology to achieve in situ delivery of biological agents in the gastrointestinal tract, and finally improve the therapeutic effect of oral engineered probiotics for psoriasis and related complications. The present invention realizes the long-term in situ delivery of biological agents in the gastrointestinal tract and oral engineered probiotics for the treatment of psoriasis and related complications, and has broad application prospects.

[0007] To achieve the above object, the present invention adopts the following technical solutions:

[0008] The first aspect of the present invention provides a recombinant plasmid, which enables host bacteria to express psoriasis therapeutic payloads (including but not limited to anti-IL-17A scFV, anti-IL-23scFV or anti-TNF-αscFV), and comprises a plasmid vector, an arabinose-responsive promoter, a bacterial protein secretion signal peptide, and a gene encoding the psoriasis therapeutic payload connected in sequence.

[0009] Among them, the nucleotide sequence of anti-IL-17A scFv is shown in SEQ ID NO.4; the nucleotide sequence of anti-IL-23 scFv is shown in SEQ ID NO.5; and the nucleotide sequence of anti-TNF-α scFv is shown in SEQ ID NO.6.

[0010] The plasmid vector is at least one of pBAD, pQE-30, pET-28a or pBR322; preferably, the plasmid vector is pBAD.

[0011] The nucleotide sequence of the arabinose-responsive promoter comprises two parts: araBAD promoter and araC; wherein the nucleotide sequence of araBAD promoter is shown in SEQ ID NO.7; and the nucleotide sequence of araC is shown in SEQ ID NO.8.

[0012] The signal peptide is at least one of PelB, Bla, MglB, OmpA, OsmY or OprI; preferably, the signal peptide is at least one of PelB, Bla or MglB; wherein the nucleotide sequence of PelB is shown in SEQ ID NO.1; the nucleotide sequence of Bla is shown in SEQ ID NO.2; and the nucleotide sequence of MglB is shown in SEQ ID NO.3.

[0013] The second aspect of the present invention provides an engineered bacterium for oral delivery of biological agents, wherein the engineered bacterium comprises a chassis bacterium and the recombinant plasmid described in the first aspect introduced into the chassis bacterium.

[0014] Wherein, the chassis bacteria include at least one of Escherichia coli Nissle1917 (EcN) and Akkermansia muciniphila (Akk).

[0015] The third aspect of the present invention provides a method for constructing an oral engineered bacterium, comprising the following steps:

[0016] (1) Synthesize the target gene fragment obtained by sequentially connecting the signal peptide gene sequence (one of SEQ ID NO.1-3), the single-chain antibody gene sequence (one of SEQ ID NO.4-6) and the HIS tag, splice them through the efficient cloning plasmid, and transform them into the plasmid recipient bacteria Escherichia coli DH-5α to obtain recombinant clones. Design PCR primers for the target sequence, perform full-length PCR synthesis reaction, and obtain the full-length sequence of the target gene containing restriction sites. Using the expression vector pBAD containing a responsive promoter as the chassis, use double restriction enzyme ligation technology to connect the target sequence to the expression plasmid, pick single clone colonies for gene identification, and obtain strains containing recombinant plasmids;

[0017] (2) extract the recombinant plasmid and transform it into competent bacteria (EcN or Akk);

[0018] (3) The ampicillin resistance gene carried on the plasmid was used for screening, and positive colonies were identified by PCR, restriction digestion and sequencing to screen out the successfully constructed engineered probiotics.

[0019] The fourth aspect of the present invention provides the use of the engineered bacteria described in the second aspect in the preparation of a biological agent for treating psoriasis and / or related complications.

[0020] Wherein, the related complications are one or both of psoriasis relapse or psoriatic arthritis.

[0021] Through the above technical solution, the present invention can at least achieve the following beneficial effects:

[0022] (1) The engineered probiotics designed and constructed by the present invention can be orally administered and can colonize in the intestinal tract for a long time, can intelligently sense the concentration of arabinose in the intestinal environment, and can secrete single-chain antibodies targeting IL-17A, which can specifically bind to IL-17A with high affinity, blocking its binding to IL-17A receptors on the surface of T cells, natural killer cells, and antigen-presenting cells, thereby blocking the immune response of downstream cells and achieving the therapeutic purpose.

[0023] (2) The present invention combines antibody-mediated immunotherapy with a simple platform capable of long-term delivery, utilizes live bacteria as delivery vectors, and takes advantage of their ability to colonize in the intestine for a long time to achieve long-term delivery of biological agents in the gastrointestinal tract.

[0024] (3) The present invention not only provides a new treatment strategy for psoriasis and related complications, but also provides a new basis for the oral administration of engineered probiotics for disease treatment. BRIEF DESCRIPTION OF THE DRAWINGS

[0025] Figure 1 The plasmid map of the plasmid pBAD-PelB-anti-IL-17A scFv-HIS constructed in Example 1;

[0026] Figure 2 The PCR results of the plasmid pBAD-PelB-anti-IL-17A scFv-HIS and the corresponding engineered bacteria in Example 2;

[0027] Figure 3 The gene sequencing result of the plasmid pBAD-PelB-anti-IL-17A scFv-HIS in Example 2;

[0028] Figure 4 This is a WB result diagram of the anti-IL-17A scFv produced by the engineered bacteria under the induction of arabinose in Example 3;

[0029] Figure 5 This is a BCA quantification graph of the anti-IL-17A scFv produced by the engineered bacteria under the induction of different arabinose concentrations in Example 3;

[0030] Figure 6 This is the IC-50 curve of the anti-IL-17A scFV produced by the engineered bacteria under the induction of arabinose in Example 3;

[0031] Figure 7 The pharmacokinetics of oral engineered bacteria and subcutaneous injection of anti-IL-17A scFv in Example 3 are compared;

[0032] Figure 8Schematic diagram of the efficiency of exocytosis of anti-IL-17A scFv by four engineered bacteria carrying three exendin peptides, PelB, Bla and MglB, and no exendin peptide (none) in Example 3;

[0033] Fig. 9 The skin lesions on the back of the psoriasis-induced model mice after oral administration of engineered probiotics in Example 4;

[0034] Fig.10 The skin lesions on the back of mice with psoriasis induced relapse after oral administration of engineered probiotics in Example 5;

[0035] Fig.11 The swelling of the knee joints of mice with psoriatic arthritis after oral administration of engineered probiotics in Example 6;

[0036] Fig.12 This is the level of IL-17A in the blood of mice with psoriatic arthritis after oral administration of engineered probiotics in Example 6. DETAILED DESCRIPTION

[0037] In order to make the purpose, technical solutions and advantages of the present invention more clearly understood, the present invention is further described in detail below in conjunction with the embodiments and the accompanying drawings.

[0038] Example 1: Construction of target gene sequence pBAD-PelB-anti-IL-17AscFv-HIS

[0039] (1) Construction of anti-IL-17A scFv gene fragment: The target gene fragment obtained by sequentially connecting the synthetic signal peptide PelB gene sequence (SEQ ID NO.1), the anti-IL-17A scFv gene sequence (SEQ ID NO.4) and the HIS tag was spliced ​​through an efficient cloning plasmid and transformed into the plasmid recipient bacterium Escherichia coli DH5α to obtain the recombinant clone PelB-anti-IL-17A scFv-HIS-DH5α;

[0040] (2) Synthesis of recombinant plasmid: Extract the whole genome gene from the recombinant clone PelB-anti-IL-17A scFv-HIS-DH5α as a template, design the PCR primers of the above target gene fragment, perform full-length PCR synthesis reaction, and obtain the full-length sequence of the target gene containing restriction sites Mlul and Ncol. Using the expression vector pBAD containing a responsive promoter as the chassis, the target gene sequence is connected to the expression vector using double restriction enzyme ligation technology, and the ligation product is transferred into competent bacteria (DH5α) by the CaCl2 method, and then transferred to LB plates containing Amp (ampicillin sodium) for culture. Pick a single clone colony for PCR identification, and transfer the correctly identified positive bacteria to LB+Amp liquid culture medium to obtain a strain containing a recombinant plasmid. From the positive bacteria correctly identified above, the recombinant plasmid pBAD-PelB-anti-IL-17A scFv-HIS (nucleotide sequence as shown in SEQ ID NO.9) was extracted using an endotoxin-free plasmid mini-extraction kit (Tiangen Biochemical Technology Co., Ltd.), as shown in FIG. Figure 1 Its plasmid map.

[0041] Construction of a recombinant plasmid using anti-IL-23scFv or anti-TNF-αscFv as a therapeutic payload: The construction method is the same as above, except that the single-chain antibody gene fragment used is replaced with the gene sequence of anti-IL-23scFv or anti-TNF-αscFv (SEQ ID NO.5-6) ​​to obtain the recombinant plasmid pBAD-PelB-anti-IL-23scFv-HIS or pBAD-PelB-TNF-αscFv-HIS.

[0042] Example 2: Construction of engineered bacteria

[0043] (1) Using Escherichia coli Nissle1917 (EcN) as the base bacteria and anti-IL-17A scFv as the therapeutic payload, the engineered bacteria were constructed: the extracted recombinant plasmid pBAD-PelB-anti-IL-23scFv-HIS was introduced into the competent E. coli EcN bacteria by high-voltage electroporation, and after transformation, it was spread on an LB plate containing 50 mg / L ampicillin sodium. After overnight culture at 37°C, the correct single clone was picked and cultured in LB liquid culture medium (containing 50 mg / L ampicillin sodium) and the plasmid was extracted and sent to BGI for sequencing verification. The positive clone strain obtained was the engineered bacteria EcN-pBAD-PelB-anti-IL-17A scFv-HIS (Ep-PIH).

[0044] like Figure 2 The PCR results of plasmid pBAD-PelB-anti-IL-17A scFv-HIS and the corresponding engineered bacteria;

[0045] like Figure 3 This is the gene sequencing result of plasmid pBAD-PelB-anti-IL-17A scFv-HIS.

[0046] (2) Construction of engineered bacteria using Escherichia coli EcN as the chassis bacteria and anti-IL-23scFv as the therapeutic payload: The construction method is the same as above, except that the recombinant plasmid is replaced with the recombinant plasmid pBAD-PelB-anti-IL-23scFv-HIS expressing anti-IL-23scFv to obtain the engineered bacteria EcN-pBAD-PelB-anti-IL-23scFv-HIS.

[0047] (3) Constructing engineered bacteria using Akkermansia muciniphila Akk as the chassis bacteria and anti-TNF-α scFv as the therapeutic payload: The construction method is the same as above, except that the competent bacteria are replaced with the competent bacteria of Akk, and the recombinant plasmid is replaced with the recombinant plasmid pBAD-PelB-anti-TNF-αscFv-HIS expressing anti-TNF-α scFv, to obtain the engineered bacteria Akk-pBAD-PelB-anti-TNF-α scFv-HIS.

[0048] Example 3: Functional verification of engineered bacteria

[0049] (1) Arabinose response performance

[0050] First, the accuracy and sensitivity of the control of the engineered bacteria arabinose sensing element were evaluated.

[0051] The engineered bacteria obtained in Example 2, such as EcN-pBAD-PelB-anti-IL-17A scFv-HIS (Ep-PIH), were induced for 12 h under conditions of no arabinose and different gradient arabinose concentrations (0%, 0.1%, 0.2%, 0.3%, 0.4%, 0.5%, 1%), and the bacterial solution was treated by ultrasonic disruption. Subsequently, Western blotting was used to detect whether there was a target band (anti-IL-17AscFv) to qualitatively determine the activation of the arabinose response switch.

[0052] like Figure 4 This is the WB result of the engineered bacteria producing anti-IL-17A scFv under the induction of arabinose. The results show that an obvious anti-IL-17A scFv band appears at 22KD.

[0053] The engineered bacteria obtained in Example 2, such as EcN-pBAD-PelB-anti-IL-17A scFv-HIS (Ep-PIH), were induced for 12 h under conditions of no arabinose and different gradient arabinose concentrations (0%, 0.1%, 0.2%, 0.3%, 0.4%, 0.5%, 1%), and the bacterial solution was treated by an ultrasonic disruptor. Subsequently, the His-tag protein purification magnetic beads (BEAVER) were used for purification and the concentration of anti-IL-17A scFv protein produced by the engineered bacteria in response to different arabinose concentration gradients was determined by the BCA method to quantitatively analyze the efficiency of the arabinose response.

[0054] like Figure 5 This is a BCA quantification graph of anti-IL-17A scFv produced by engineered bacteria under the induction of different arabinose concentrations. It can be found that as the concentration of arabinose increases, the content of anti-IL-17A scFv produced by the engineered bacteria gradually increases.

[0055] (2) Functional verification of the expressed therapeutic payload

[0056] The anti-IL-17A scFv produced by the engineered bacteria, such as EcN-pBAD-PelB-anti-IL-17A scFv-HIS (Ep-PIH), was purified using the HIS purification tag and its antagonistic ability against IL-17A was evaluated.

[0057] Purified anti-IL-17A scFv of different concentrations were mixed with sufficient IL-17A and incubated for 12 hours. The IL-17A concentration was detected using an IL-17A ELISA kit to reflect the antagonistic performance of the anti-IL-17A scFV.

[0058] like Figure 6 This is the IC-50 curve of the anti-IL-17A scFV produced by Ep-PIH. The results show that the half-inhibitory concentration of the anti-IL-17A scFv produced by the engineered bacteria is 0.5734 nM, which has good antagonistic performance against IL-17A.

[0059] (3) Verification of the long-term drug release performance of engineered bacteria

[0060] To further evaluate the long-term drug release performance brought about by the colonization of engineered bacteria such as EcN-pBAD-PelB-anti-IL-17A scFv-HIS (Ep-PIH), mice were subcutaneously injected with anti-IL-17A scfv and orally administered with engineered bacteria Ep-PIH, and the concentrations of single-chain antibodies in serum at different time points were measured for pharmacokinetic comparison.

[0061] like Figure 7 The curves of serum anti-IL-17A scFv concentrations produced by subcutaneous injection of anti-IL-17A scFv and oral administration of engineered bacteria Ep-PIH were plotted over time (0-72 days) for mice. The results showed that compared with subcutaneous injection, oral administration of the anti-IL-17A scFv produced by the engineered bacteria could maintain an effective concentration range for a longer period of time, and the effect was more lasting.

[0062] (4) Verification of exendin efficiency

[0063] In order to evaluate the efficiency of the three exendin peptides that were screened and optimized to be most conducive to the function of the recombinant protein expression system, including PelB, Bla and MglB, three corresponding recombinant plasmids were synthesized, such as anti-IL-17A scFv as the therapeutic load, and transformed into chassis bacteria such as EcN, respectively, to obtain the engineered bacteria EcN-pBAD-PelB-anti-IL-17A scFv-HA, EcN-pBAD-Bla-anti-IL-17A scFv-HA and EcN-pBAD-MglB-anti-IL-17A scFv-HA, as well as the recombinant plasmid without any exendin peptide and its engineered bacteria EcN-pBAD-anti-IL-17A scFv-HA. After the same degree of culture and 0.5% arabinose induction, the anti-IL-17A scfv level in the bacterial culture supernatant and lysate supernatant was determined by HA Elisa kit.

[0064] like Figure 8 Schematic diagram of the efficiency of exocytosis of anti-IL-17A scFv by four engineered bacteria carrying three exendin peptides PelB, Bla and MglB and none (none). The results show that the three exendin peptides PelB, Bla and MglB obtained by screening and optimization can increase the exocytosis efficiency of anti-IL-17A scFv by 5 times and reach a similar level. Therefore, oral administration of the engineered bacteria can make the therapeutic payload more effectively secreted out of the bacteria and exert its function more effectively.

[0065] Example 4: Oral administration of engineered probiotics for the treatment of psoriasis

[0066] The mice were subjected to relevant hair removal treatment on their backs. A pet shaver was used to remove the hair first, and then Veet depilatory was used to thoroughly remove the hair on the back to obtain 3*3cm smooth skin. The treated mice were raised normally for 2 days to eliminate the possible effects of the shaver and depilatory on the skin on the back of the mice.

[0067] Mice were randomly divided into 4 groups:

[0068] (1) Blank group: oral administration for 109 engineered probiotics and oral administration of 1 mL of 0.5 mg / mL arabinose aqueous solution per day;

[0069] (2) Model group: 62.5 mg of 5% IMQ cream was applied to the back of mice daily, and 1 mL of 0.5 mg / mL arabinose aqueous solution was orally administered daily;

[0070] (3) Positive drug group: Oral administration of 10 mg / kg on the day before induction 9 For wild-type probiotics, 62.5 mg of 5% IMQ cream was applied to the back of mice daily, and 1 mL of 0.5 mg / mL arabinose aqueous solution was orally administered daily;

[0071] (4) Treatment group: Oral administration of 10 mg / kg on the day before induction 9 The engineered probiotics obtained in Example 2 were applied to the back of mice with 62.5 mg of 5% IMQ cream daily, and 1 mL of 0.5 mg / mL arabinose aqueous solution was orally administered daily.

[0072] There were 6 mice in each group, and all treatments started from the day of IMQ application (day 0) and were given once a day for 7 consecutive days.

[0073] After the experiment, the mice were killed by cervical dislocation, and the back skin lesion tissue and eye blood were collected for further experiments.

[0074] like Fig. 9 The results of the study on the back skin lesions of psoriasis-induced model mice after treatment with engineered bacteria such as EcN-pBAD-PelB-anti-IL-17A scFv-HIS (Ep-PIH) showed that the therapeutic effect of probiotics alone was poor, while the engineered bacteria designed and constructed in this project showed obvious psoriasis treatment effects, and the skin lesion rate on the back of mice was significantly reduced.

[0075] Example 5: Oral administration of engineered probiotics for the treatment of relapse of psoriasis

[0076] The mice were subjected to relevant hair removal treatment on their backs. A pet shaver was used to remove the hair first, and then Veet depilatory was used to thoroughly remove the hair on the back to obtain 3*3cm smooth skin. The treated mice were raised normally for 2 days to eliminate the possible effects of the shaver and depilatory on the skin on the back of the mice.

[0077] Mice were randomly divided into 5 groups:

[0078] (1) Blank group: oral administration for 10 9 engineered probiotics and oral administration of 1 mL of 0.5 mg / mL arabinose aqueous solution per day;

[0079] (2) Non-relapse treatment group: Orally take 10 9The engineered probiotics obtained in Example 2 were applied to the back of mice daily with 62.5 mg of 5% IMQ cream, and 1 mL of 0.5 mg / mL arabinose aqueous solution was orally administered daily;

[0080] (3) Model group: 62.5 mg of 5% IMQ cream was applied to the back of mice daily, and 1 mL of 0.5 mg / mL arabinose aqueous solution was orally administered daily;

[0081] (4) Positive drug group: Orally take 10 9 For wild-type probiotics, 62.5 mg of 5% IMQ cream was applied to the back of mice daily, and 1 mL of 0.5 mg / mL arabinose aqueous solution was orally administered daily;

[0082] (5) Treatment group: Oral administration of 10 mg / kg on the day before induction 9 The engineered probiotics obtained in Example 2 were applied to the back of mice with 62.5 mg of 5% IMQ cream daily, and 1 mL of 0.5 mg / mL arabinose aqueous solution was orally administered daily.

[0083] There were 6 mice in each group. All treatments started from the day of IMQ application (day 0) and were administered once a day for 7 consecutive days. The mice recovered for 30 days, and then the relapse model was induced again in the model group, positive drug group and treatment group mice at the same lesion site using 20.8 mg IMQ per day for 10 consecutive days.

[0084] After the experiment, the mice were killed by cervical dislocation, and the back skin lesion tissue and eye blood were collected for further experiments.

[0085] like Fig.10 This is the skin lesions on the back of mice with psoriasis relapse model after treatment. The results show that the treatment effect of using probiotics alone is not good, while the engineered bacteria designed and constructed in this project showed obvious inhibitory effect on psoriasis relapse.

[0086] Example 6: Oral administration of engineered probiotics for the treatment of psoriatic arthritis

[0087] Zymosan was injected into the peritoneum of 8-10 week old female SKG mice (BAREB / c mice are genetic mutants, carrying mutant ZAP-70 gene, and CD4+T cell development in the thymus is arrested). After 8 weeks of feeding in a sterile environment, peripheral arthritis gradually appeared, and bone destruction and new bone formation were examined by micro-CT.

[0088] The mice were randomly divided into four groups:

[0089] (1) Blank group: oral administration for 10 9 engineered probiotics and oral administration of 1 mL of 0.5 mg / mL arabinose aqueous solution per day;

[0090] (2) Model group: psoriatic arthritis was induced by zymosan every day, and 1 mL of 0.5 mg / mL arabinose aqueous solution was taken orally every day;

[0091] (3) Positive drug group: Oral administration of 10 mg / kg on the day before induction 9 wild-type probiotics, daily intraperitoneal injection of zymosan, and oral administration of 1 mL of 0.5 mg / mL arabinose aqueous solution;

[0092] (4) Treatment group: Oral administration of 10 mg / kg on the day before induction 9 The engineered probiotics obtained in Example 2 were intraperitoneally injected with zymosan daily, and 1 mL of a 0.5 mg / mL arabinose aqueous solution was orally administered daily.

[0093] There were 6 mice in each group, and all treatments started from the day of zymosan application (day 0) and were given once a day for 8 consecutive weeks.

[0094] After the experiment, the mice were killed by cervical dislocation, and joint bones and eye blood were collected for further experiments.

[0095] like Fig.11 The swelling of the knee joints of mice with psoriatic arthritis model after treatment was compared with that before treatment. Fig.12 This is the blood IL-17A factor of mice with psoriatic arthritis after treatment. The results show that the treatment effect of probiotics alone is not good, while the engineered bacteria designed and constructed in this project show obvious inhibitory effect on psoriatic arthritis.

Claims

1. A recombinant plasmid, It is characterized in that The invention comprises a plasmid vector, an arabinose-responsive promoter, a signal peptide and a coding gene of a single-chain antibody which are connected in sequence; The single-chain antibody is a psoriasis therapeutic payload.

2. A recombinant plasmid as claimed in claim 1, It is characterized in that The single-chain antibody is at least one of anti-IL-17AscFv, anti-IL-23scFv or anti-TNF-αscFv; Wherein, the nucleotide sequence of anti-IL-17A scFv is shown in SEQ ID NO.4; The nucleotide sequence of anti-IL-23scFv is shown in SEQ ID NO.5; The nucleotide sequence of anti-TNF-α scFv is shown in SEQ ID NO.

6.

3. A recombinant plasmid as claimed in claim 1, It is characterized in that The plasmid vector is at least one of pBAD, pQE-30, pET-28a or pBR322; Preferably, the plasmid vector is pBAD.

4. A recombinant plasmid as claimed in claim 1, It is characterized in that The nucleotide sequence of the arabinose-responsive promoter includes two parts: araBAD promoter and araC; Wherein, the nucleotide sequence of araBAD promoter is shown in SEQ ID NO.7; The nucleotide sequence of araC is shown in SEQ ID NO.

8.

5. A recombinant plasmid as claimed in claim 1, It is characterized in that The signal peptide is at least one of PelB, Bla, MglB, OmpA, OsmY or OprI; Preferably, the signal peptide is at least one of PelB, Bla or MglB; Wherein, the nucleotide sequence of PelB is shown in SEQ ID NO.1; The nucleotide sequence of Bla is shown in SEQ ID NO.2; The nucleotide sequence of MglB is shown in SEQ ID NO.

3.

6. A recombinant plasmid as claimed in claim 1, It is characterized in that The nucleotide sequence of the recombinant plasmid is shown in SEQ ID NO.

9.

7. An oral engineered bacterium, It is characterized in that The engineered bacteria include chassis bacteria and a recombinant plasmid introduced into the chassis bacteria; The recombinant plasmid is as described in any one of claims 1-6.

8. An oral engineered bacterium as claimed in claim 7, It is characterized in that The chassis bacteria is at least one of Escherichia coli Nissle1917 or Akkermansia muciniphila.

9. Use of the recombinant plasmid according to any one of claims 1 to 6, or the oral engineered bacteria according to claim 7, in the preparation of a biological agent for treating psoriasis and / or related complications.

10. The use according to claim 9, It is characterized in that The related complications are psoriasis relapse or psoriatic arthritis.